854 related articles for article (PubMed ID: 28802913)
1. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy.
Chapman CH; Maghsoudi K; Littell RD; Chen LM; Hsu IC
Brachytherapy; 2017; 16(6):1152-1158. PubMed ID: 28802913
[TBL] [Abstract][Full Text] [Related]
2. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
[TBL] [Abstract][Full Text] [Related]
3. MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer.
Kamran SC; Manuel MM; Catalano P; Cho L; Damato AL; Lee LJ; Schmidt EJ; Viswanathan AN
Brachytherapy; 2017; 16(6):1159-1168. PubMed ID: 28823395
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.
Ling DC; Vargo JA; Glaser SM; Kim H; Beriwal S
Gynecol Oncol; 2019 Mar; 152(3):581-586. PubMed ID: 30600093
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes following 3D image-guided brachytherapy for vaginal recurrence of endometrial cancer.
Lee LJ; Damato AL; Viswanathan AN
Gynecol Oncol; 2013 Dec; 131(3):586-92. PubMed ID: 24029418
[TBL] [Abstract][Full Text] [Related]
6. Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer.
Baek S; Isohashi F; Yamaguchi H; Mabuchi S; Yoshida K; Kotsuma T; Yamazaki H; Tanaka E; Sumida I; Tamari K; Otani K; Seo Y; Suzuki O; Yoshioka Y; Kimura T; Ogawa K
Brachytherapy; 2016; 15(6):812-816. PubMed ID: 27614661
[TBL] [Abstract][Full Text] [Related]
7. Treatment of vaginal recurrences in endometrial carcinoma by high-dose-rate brachytherapy.
Sorbe B; Söderström K
Anticancer Res; 2013 Jan; 33(1):241-7. PubMed ID: 23267151
[TBL] [Abstract][Full Text] [Related]
8. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence.
Petignat P; Jolicoeur M; Alobaid A; Drouin P; Gauthier P; Provencher D; Donath D; Van Nguyen T
Gynecol Oncol; 2006 Jun; 101(3):445-9. PubMed ID: 16386785
[TBL] [Abstract][Full Text] [Related]
9. Perineal template interstitial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina.
Nag S; Martínez-Monge R; Copeland LJ; Vacarello L; Lewandowski GS
Gynecol Oncol; 1997 Jul; 66(1):16-9. PubMed ID: 9234914
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer.
Sapienza LG; Ning MS; de la Pena R; McNew LK; Jhingran A; Georgeon L; Rasool N; Gomes MJL; Abu-Isa E; Baiocchi G
Int J Gynecol Cancer; 2020 Oct; 30(10):1535-1541. PubMed ID: 32376738
[TBL] [Abstract][Full Text] [Related]
11. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
12. Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy.
Jereczek-Fossa B; Badzio A; Jassem J
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):405-13. PubMed ID: 10974454
[TBL] [Abstract][Full Text] [Related]
13. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
14. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate interstitial brachytherapy for the treatment of high-volume locally recurrent endometrial carcinoma.
Huang K; D'Souza D; Patil N; Velker V; Leung E; Stitt L; Whiston F; Sugimoto A; McGee J; Prefontaine M
Brachytherapy; 2016; 15(5):543-8. PubMed ID: 27475479
[TBL] [Abstract][Full Text] [Related]
16. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer.
Lin LL; Grigsby PW; Powell MA; Mutch DG
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):500-4. PubMed ID: 16168841
[TBL] [Abstract][Full Text] [Related]
17. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
19. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
20. Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1-2, stage IC endometrial cancer.
Cengiz M; Singh AK; Grigsby PW
Int J Gynecol Cancer; 2005; 15(5):926-31. PubMed ID: 16174247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
